1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

Immune Response BioPharma Terminates Blockbuster MS Drug NeuroVax Partnership Discussions with GSK

Immune Response BioPharma, Inc. Terminates Blockbuster MS Drug NeuroVax Partnership Discusions With GSK

 
PRLog - May 24, 2012 - NEW YORK -- Immune Response BioPharma, Inc. Terminates Blockbuster MS Drug NeuroVax Partnership Discusions With GSK.

"Immune Response BioPharma, Inc. has the first MS Vaccine a first in class and best in class multiple sclerosis drug which restores deficient FOXP3+ T-Regs. GSK has no approved MS drug and probably will never have one they are busy wasting their shareholders money on HGSI and a Lupus drug with poor sales, we don't need them or to give away our blockbuster drug for MS to them which we believe will become treatment of choice" IRBP CEO Mr. Buswell

"IRBP values NeuroVax north of a billion dollar of annual sales once approved. We will find a solid partner or raise capital on our own, we don't need GSK which has zer0 experience in multiple sclerosis or auto-immune diseases. GSK is a joke and seems very ignorant on how multiple sclerosis drugs work and how to develop one, we gave them a chance to develop NeuroVax but their management appears to be very poor. We have decided to terminate any collaboration or development with GSK. GSK is a loser in the MS market and will continue to be a loser" IRBP CEO Mr. Buswell

www.immuneresponsebiopharma.com

--- End ---

Click to Share

Contact Email:
***@immuneresponsebiopharma.com Email Verified
Source:Immune Response BioPharma, Inc.
Phone:(917) 275-7931
Zip:10001
City/Town:New York City - New York - United States
Industry:Health
Tags:immune response biopharma, MS multiple sclerosis, vaccine
Shortcut:prlog.org/11883928
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share